2022开门红,恒旭资本投资的亚虹医药在科创板成功上市

2022-01-07

今天,由恒旭资本投资的亚虹医药科技有限公司(以下简称“亚虹医药”)在上海证券交易所科创板上市,公司证券代码:688176。2022年伊始,恒旭资本迎来IPO开门红。


image.png


关于亚虹医药 

image.png

亚虹医药成立于2010年3月,是一家专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化创新药公司。 秉承“改善人类健康,让生命更有尊严”的企业使命,亚虹立志成为在专注治疗领域集研发、生产和商业化为一体的国际领先制药企业,为中国和全球患者提供最佳的诊疗一体化解决方案。


 公司坚持以创新技术和产品为核心驱动力,通过打造自有的研发平台和核心技术,深入探索药物作用机理,高效率筛选评价候选药物。通过内部完善的研发体系和全球药物开发经验专长,亚虹致力于在专注治疗领域推出全球首创(First-in-Class)药物和其它存在巨大未被满足治疗需求的创新药物。


恒旭资本董事长陆永涛表示:“亚虹医药所在的泌尿系统肿瘤治疗临床未被满足需求巨大,可用的创新药稀缺,公司处于良好的竞争格局,极具稀缺性,且公司管理团队经验丰富、执行力强,已经在海外进行了广泛布局,立志于成为面向全球的创新药研发、生产和销售企业。恒旭资本作为亚虹医药的投资人,围绕其产品上下游进行布局,寻找与亚虹医药潜在合作的新产品,构建生态圈覆盖所在领域早中期企业。” 


该项目的成功上市也充分践行了恒旭资本的投资理念。未来,恒旭资本将发挥产业资源和专业优势,继续支持亚虹医药发展,助力其成为全球领先的创新药企业,造福更多的中国和全球患者。

Top

Statement:

It has been discovered that some entities or individuals maliciously impersonate our company and our employees, and conduct illegal financing through live broadcasts on the internet to profit illegally. Such illegal behavior has seriously damaged our image. We kindly remind you not to believe in information released other than our official channels, official channels of Hengxu Capital include - website: www.hengxucapital.com; WeChat account: Hengxu Capital (ID: Hengxucapital). Our solemn statement:

 

1.Illegal behavior carried out by anyone who impersonates our company or our employees will be subject to legal action and take legal responsibility for rights infringement, we pursue protecting the legitimate rights and interests of our company and our personnel. Hengxu Capital will not tolerate such illegal activities, we have taken and will continue to take legal action to pursue the legal responsibility of individuals or entities engaged in such illegal activities.

 

2.Hengxu Capital is a private equity and venture capital fund manager registered with Asset Management Association of China, and conducts business strictly in accordance with relevant regulatory requirements. To avoid losses, we would like to remind investors to be vigilant and invest through legal and legitimate channels, and not believe in false information obtained from non-official channels of Hengxu Capital.

 

3.Thank you for your kind support and attention. If you find any abnormal identity or information, please contact us for verification in a timely manner. At the same time, we encourage you to actively provide information and report aforementioned illegal activities at +86-21-22016849. Victim is requested to report to local police promptly to protect your own interests, and  ensure offenders are held accountable as soon as possible.

 

Shanghai SAIC Hengxu Capital Co., Ltd.

Aug. 22, 2022